These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 7554034)

  • 21. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Menstrual breakdown of human endometrium can be mimicked in vitro and is selectively and reversibly blocked by inhibitors of matrix metalloproteinases.
    Marbaix E; Kokorine I; Moulin P; Donnez J; Eeckhout Y; Courtoy PJ
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9120-5. PubMed ID: 8799164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates.
    Roycik MD; Fang X; Sang QX
    Curr Pharm Des; 2009; 15(12):1295-308. PubMed ID: 19355969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds.
    Chambers L; Woodrow S; Brown AP; Harris PD; Phillips D; Hall M; Church JC; Pritchard DI
    Br J Dermatol; 2003 Jan; 148(1):14-23. PubMed ID: 12534589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutral proteinases and their inhibitors in the loosening of total hip prostheses.
    Takagi M
    Acta Orthop Scand Suppl; 1996 Oct; 271():3-29. PubMed ID: 8975533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloproteinases and their inhibitors in tumour growth and invasion.
    Kähäri VM; Saarialho-Kere U
    Ann Med; 1999 Feb; 31(1):34-45. PubMed ID: 10219712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinases in cerebrovascular disease.
    Mun-Bryce S; Rosenberg GA
    J Cereb Blood Flow Metab; 1998 Nov; 18(11):1163-72. PubMed ID: 9809504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular matrix remodelling and cellular differentiation.
    Streuli C
    Curr Opin Cell Biol; 1999 Oct; 11(5):634-40. PubMed ID: 10508658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer: the matrix is now in control.
    Comoglio PM; Trusolino L
    Nat Med; 2005 Nov; 11(11):1156-9. PubMed ID: 16270068
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.
    Odake S; Morita Y; Morikawa T; Yoshida N; Hori H; Nagai Y
    Biochem Biophys Res Commun; 1994 Mar; 199(3):1442-6. PubMed ID: 8147888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of matrix metalloproteinases and their inhibitor in the articular disc of the craniomandibular joint of the rabbit.
    Breckon JJ; Hembry RM; Reynolds JJ; Meikle MC
    Arch Oral Biol; 1996 Apr; 41(4):315-22. PubMed ID: 8771322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases.
    Imai K; Kusakabe M; Sakakura T; Nakanishi I; Okada Y
    FEBS Lett; 1994 Sep; 352(2):216-8. PubMed ID: 7523186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of matrix metalloproteinase inhibitor on pseudomonal proteinases].
    Kosaku K; Maeda N; Yokoyama T; Inoue T; Yoshida Y; Hosokawa T; Sawa M
    Nippon Ganka Gakkai Zasshi; 1998 Feb; 102(2):83-7. PubMed ID: 9513352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases.
    Baramova EN; Shannon JD; Bjarnason JB; Fox JW
    Arch Biochem Biophys; 1989 Nov; 275(1):63-71. PubMed ID: 2817904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteases and protease inhibitors in tumor progression.
    DeClerck YA; Imren S; Montgomery AM; Mueller BM; Reisfeld RA; Laug WE
    Adv Exp Med Biol; 1997; 425():89-97. PubMed ID: 9433492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase.
    Schwartz JD; Shamamian P; Monea S; Whiting D; Marcus SG; Galloway AC; Mignatti P
    Surgery; 1998 Aug; 124(2):232-8. PubMed ID: 9706143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reelin, the extracellular matrix protein deficient in reeler mutant mice, is processed by a metalloproteinase.
    Lambert de Rouvroit C; de Bergeyck V; Cortvrindt C; Bar I; Eeckhout Y; Goffinet AM
    Exp Neurol; 1999 Mar; 156(1):214-7. PubMed ID: 10192793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion.
    Varani J; Burmeister B; Sitrin RG; Shollenberger SB; Inman DR; Fligiel SE; Gibbs DF; Johnson K
    Am J Pathol; 1994 Sep; 145(3):561-73. PubMed ID: 8080040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Collagenase: a key enzyme in collagen turnover.
    Shingleton WD; Hodges DJ; Brick P; Cawston TE
    Biochem Cell Biol; 1996; 74(6):759-75. PubMed ID: 9164646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteases decode the extracellular matrix cryptome.
    Ricard-Blum S; Vallet SD
    Biochimie; 2016 Mar; 122():300-13. PubMed ID: 26382969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.